Skip to main content
SpringerLink
Log in

Benzimidavir

1263W94, BW 1263W94, GW 1263

  • Section 1: Cytomegalovirus Retiniti
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Koszalka GW, Chamberlain SD, Harvey RJ, et al. Benzimidazoles for the treatment of human cytomegalovirus. Antiviral Res 1996 Apr; 30: 43

    Google Scholar 

  2. Wang LH, Lyogendran S, Weller S, et al. A phase I trial evaluating the tolerability and pharmacokinetics of 1263W94 following single oral administration of escalating doses in normal healthy volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996 Sep 15–18; New Orleans, 168

    Google Scholar 

  3. Drew WL, Lalezari JP, Wang LH, et al. In vivo anti-CMV activity and safety of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding. Antiviral Res 1998 Mar; 37: 70

    Google Scholar 

  4. Selleseth DW, Talarico CL, Lutz MW, et al. Interactions of GW1263 with other antiviral agents in the inhibition of the HCMV. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28–Oct 1; Toronto, 225

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benzimidavir. Drugs R&D 2, 306–307 (1999). https://doi.org/10.2165/00126839-199902050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902050-00004

Keywords

Search

Navigation